Cornerstone Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $29.1M | Buy |
+115,825
| New | +$24.9M | 0.96% | 24 |
|
|
2025
Q4 | – | Sell |
-126,200
| Closed | -$29.2M | – | 159 |
|
|
2025
Q3 | $29.2M | Sell |
126,200
-2,200
| -2% | -$448K | 0.96% | 23 |
|
|
2025
Q2 | $23.8M | Buy |
128,400
+42,000
| +49% | +$7.81M | 0.82% | 28 |
|
|
2025
Q1 | $18.1M | Buy |
86,400
+4,200
| +5% | +$816K | 0.78% | 30 |
|
|
2024
Q4 | $14.6M | Buy |
82,200
+600
| +0.7% | +$110K | 0.58% | 35 |
|
|
2024
Q3 | $16.1M | Buy |
81,600
+1,500
| +2% | +$280K | 0.64% | 35 |
|
|
2024
Q2 | $13.7M | Hold |
80,100
| – | – | 0.56% | 40 |
|
|
2024
Q1 | $14.6M | Buy |
80,100
+400
| +0.5% | +$68.9K | 0.6% | 37 |
|
|
2023
Q4 | $12.4M | Sell |
79,700
-6,300
| -7% | -$918K | 0.54% | 42 |
|
|
2023
Q3 | $12.8M | Buy |
+86,000
| New | +$12.6M | 0.6% | 33 |
|
|
2023
Q2 | – | Sell |
-26,600
| Closed | -$4.24M | – | 261 |
|
|
2023
Q1 | $4.24M | Buy |
26,600
+20,000
| +303% | +$3.06M | 0.2% | 113 |
|
|
2022
Q4 | $1.07M | Sell |
6,600
-105,900
| -94% | -$16.2M | 0.05% | 165 |
|
|
2022
Q3 | $15.1M | Hold |
112,500
| – | – | 0.74% | 34 |
|
|
2022
Q2 | $17.2M | Buy |
112,500
+13,500
| +14% | +$2.06M | 0.9% | 30 |
|
|
2022
Q1 | $16M | Hold |
99,000
| – | – | 0.95% | 21 |
|
|
2021
Q4 | $13.4M | Hold |
99,000
| – | – | 0.73% | 36 |
|
|
2021
Q3 | $10.7M | Buy |
+99,000
| New | +$11.3M | 0.62% | 46 |
|
|
2021
Q2 | – | Sell |
-131,000
| Closed | -$14.2M | – | 192 |
|
|
2021
Q1 | $14.2M | Hold |
131,000
| – | – | 1.24% | 16 |
|
|
2020
Q4 | $14M | Hold |
131,000
| – | – | 1.23% | 16 |
|
|
2020
Q3 | $11.5M | Buy |
131,000
+25,000
| +24% | +$2.35M | 1.03% | 21 |
|
|
2020
Q2 | $10.4M | Buy |
106,000
+96,000
| +960% | +$8.45M | 0.97% | 26 |
|
|
2020
Q1 | $762K | Buy |
+10,000
| New | +$852K | 0.08% | 144 |
|
|
2018
Q4 | – | Sell |
-144,000
| Closed | -$13.6M | – | 224 |
|
|
2018
Q3 | $13.6M | Buy |
144,000
+27,000
| +23% | +$2.56M | 0.98% | 28 |
|
|
2018
Q2 | $10.8M | Hold |
117,000
| – | – | 1.31% | 19 |
|
|
2018
Q1 | $11.1M | Hold |
117,000
| – | – | 1.32% | 15 |
|
|
2017
Q4 | $11.3M | Hold |
117,000
| – | – | 1.29% | 15 |
|
|
2017
Q3 | $10.4M | Buy |
+117,000
| New | +$8.91M | 1.2% | 20 |
|
|
2016
Q3 | – | Sell |
-22,200
| Closed | -$1.37M | – | 207 |
|
|
2016
Q2 | $1.37M | Hold |
22,200
| – | – | 0.34% | 81 |
|
|
2016
Q1 | $1.27M | Sell |
22,200
-5,000
| -18% | -$279K | 0.31% | 90 |
|
|
2015
Q4 | $1.61M | Hold |
27,200
| – | – | 0.37% | 81 |
|
|
2015
Q3 | $1.48M | Buy |
27,200
+5,000
| +23% | +$325K | 0.35% | 87 |
|
|
2015
Q2 | $1.49M | Hold |
22,200
| – | – | 0.33% | 86 |
|
|
2015
Q1 | $1.3M | Hold |
22,200
| – | – | 0.27% | 101 |
|
|
2014
Q4 | $1.45M | Hold |
22,200
| – | – | 0.29% | 98 |
|
|
2014
Q3 | $1.28M | Hold |
22,200
| – | – | 0.25% | 118 |
|
|
2014
Q2 | $1.25M | Hold |
22,200
| – | – | 0.25% | 119 |
|
|
2014
Q1 | $1.14M | Hold |
22,200
| – | – | 0.27% | 110 |
|
|
2013
Q4 | $1.17M | Hold |
22,200
| – | – | 0.29% | 102 |
|
|
2013
Q3 | $993K | Hold |
22,200
| – | – | 0.32% | 95 |
|
|
2013
Q2 | $918K | Buy |
+22,200
| New | +$971K | 0.36% | 85 |
|
Other funds holding ABBV
Cornerstone Advisors's ABBV Position: Q2 2026 in Review
Cornerstone Advisors opened a new position in AbbVie (ABBV) in Q2 2026: 115,825 shares worth $29.1M. The stake represents 0.96% of the portfolio and ranks #24 among its holdings. This is a return to the name: Cornerstone Advisors previously reported a position in ABBV as recently as Q3 2025.
Cornerstone Advisors first reported a position in ABBV in Q2 2013 and has held it in 40 quarters since. The position peaked at $29.2M in Q3 2025. 2,841 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Cornerstone Advisors held 115,825 shares of AbbVie worth $29.1M as of Q2 2026.
- AbbVie was a new Cornerstone Advisors position in Q2 2026.
- AbbVie made up 0.96% of Cornerstone Advisors's portfolio in Q2 2026, its #24 holding.
- Cornerstone Advisors first reported a position in AbbVie in Q2 2013 and has held it in 40 quarters since.
- Cornerstone Advisors's AbbVie position peaked at $29.2M in Q3 2025.
- 2,841 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Cornerstone Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.